chapter
review
develop
inhibitor
viral
proteas
major
focu
inhibitor
proteas
target
seen
greatest
amount
work
mani
biolog
lesson
learn
directli
applic
viral
system
major
limit
antivir
therapi
develop
inhibitor
resist
topic
also
consid
gener
review
antivir
resist
also
refer
proteas
inhibitor
provid
chap
book
space
permit
comprehens
referenc
therefor
cite
semin
initi
report
refer
comprehens
review
articl
discuss
recent
publish
literatur
final
although
mani
virus
encod
essenti
proteas
focu
virus
drug
develop
either
like
progress
clinic
viral
proteas
part
common
strategi
synthesi
larg
precursor
protein
cleav
gener
matur
activ
protein
viral
proteas
deriv
wellknown
eukaryot
proteas
famili
evolv
specif
thu
catalyt
mechan
peptid
bond
cleavag
follow
well
known
chemistri
catalyz
canon
activ
site
residu
specif
site
cleavag
determin
interact
proteas
amino
acid
side
chain
flank
site
cleavag
ie
scissil
bond
drug
design
take
advantag
known
featur
catalyt
mechan
add
specif
base
flank
interact
guid
part
structur
inform
given
start
point
design
proteas
inhibitor
typic
proceed
largescal
screen
substratelik
molecul
requir
proteas
inhibitor
drug
term
potenc
pharmacokinet
toxic
vari
depend
natur
infect
goal
therapi
one
extrem
treatment
chronic
infect
requir
lifelong
therapi
full
suppress
viral
replic
extrem
treatment
human
rhinoviru
ie
cold
viru
shortterm
treatment
blunt
viremia
like
suffici
reduc
unwant
symptom
cold
case
viral
proteas
repres
attract
target
familiar
mechan
catalysi
frequent
allow
design
transit
state
analog
distinct
specif
host
proteas
main
featur
proteas
express
process
review
swanstrom
will
proteas
encod
viral
pro
gene
locat
downstream
gag
gene
upstream
pol
gene
encod
viral
polymeras
integras
express
part
larg
polyprotein
precursor
gagpropol
precursor
given
dimer
natur
viral
proteas
clear
gagpropol
precursor
must
dimer
allow
proteas
becom
activ
detail
proteas
excis
precursor
poorli
understood
although
initi
cleavag
appear
occur
ci
novel
cleavag
site
pettit
et
al
proteas
like
retrovir
proteas
homodimer
aspartyl
proteas
see
fig
activ
site
form
dimer
interfac
two
aspart
acid
locat
base
activ
site
enzymat
mechan
thought
classic
acidbas
catalysi
involv
water
molecul
call
pushpul
mechan
water
molecul
thought
transfer
proton
dyad
carboxyl
group
aspart
acid
proton
dyad
transfer
peptid
bond
cleav
mechan
tetrahedr
intermedi
transient
exist
nonconval
mimick
current
use
fda
approv
inhibitor
distinct
featur
proteas
presenc
mobil
beta
turn
subunit
serv
flap
cover
activ
site
substrat
get
access
activ
site
flap
move
away
must
ongo
dynam
fig
ribbon
diagram
crystal
structur
substrat
complex
homodim
proteas
prabujeyabalan
et
al
monom
shown
cyan
pink
substrat
shown
green
catalyt
aspart
acid
highlight
yellow
process
substrat
recogn
bound
flap
move
back
activ
site
lock
bound
substrat
complet
activ
site
caviti
permit
substrat
cleavag
proteas
cleav
gag
gagpropol
polyprotein
ten
site
enzym
recogn
seri
eight
residu
substrat
cleavag
site
rang
nearli
substrat
buri
within
activ
site
prabujeyabalan
et
al
sequenc
ten
substrat
site
quit
divers
cleav
differ
effici
substrat
site
branch
amino
acid
residu
site
hydrophob
residu
aromat
prolin
howev
except
pattern
cleavag
site
last
slowest
site
cleav
process
gag
alanin
asparagin
differ
substrat
sequenc
result
cleavag
rate
nearli
differ
cleavag
effici
differ
rate
coupl
togeth
threedimension
topolog
polyprotein
like
contribut
sequenti
order
substrat
cleav
crystallograph
studi
impli
although
littl
sequenc
homolog
exist
differ
proteas
cleavag
site
conserv
shape
adopt
within
activ
site
enzym
prabujeyabalan
et
al
shape
term
substrat
envelop
repres
consensu
volum
overlap
major
substrat
like
proteas
recogn
particular
peptid
sequenc
substrat
combin
access
shape
sequenc
adopt
develop
proteas
inhibitor
pi
repres
highli
success
effort
drug
discoveri
nine
pi
current
approv
fda
sever
clinic
trial
initi
lead
pi
found
within
pharmaceut
compani
librari
develop
anoth
pharmaceut
interest
aspartyl
proteas
renin
initi
lead
compound
knowledg
cleavag
site
sequenc
known
catalyt
mechan
generaliz
strategi
gener
transit
state
analog
abil
readili
crystal
proteas
bound
inhibitor
provid
tool
necessari
success
ongo
drug
develop
effort
proteas
first
therapeut
target
structurebas
drug
design
broadli
use
optim
inhibitor
design
wlodaw
erickson
potenti
lead
compound
cocrystal
complex
enzym
new
compound
design
better
fit
complement
interact
within
activ
site
race
develop
pi
compet
laboratori
would
cocrystal
compound
competitor
patent
order
figur
altern
chemic
scaffold
would
preserv
contact
better
pharmacokinet
bioavail
result
mani
pi
occupi
fill
activ
site
highli
overlap
manner
inhibitor
fairli
hydrophob
gener
fit
region
activ
site
often
hydrophob
cyclic
side
chain
fairli
bulki
function
group
nine
fdaapprov
pi
competit
activ
site
inhibitor
bind
affin
purifi
enzym
rang
low
nanomolar
low
picomolar
fig
chen
et
al
kaldor
fig
threedimension
structur
nine
current
fdaapprov
proteas
inhibitor
color
atomtyp
whitecarbon
bluenitrogen
redoxygen
yellowsulfur
purpleflorin
figur
made
pymol
delano
sqv
saquinavir
apv
amprenavir
atv
atazanavir
nfv
nelifinavir
drv
darunavir
rtv
ritonavir
idv
indinavir
tpv
tipranavir
lpv
lopinavir
et
al
kempf
et
al
krohn
et
al
stoll
et
al
thaisrivong
strohbach
seven
nine
inhibitor
except
tipranavir
darunavir
peptidomimet
mimic
enzymat
transit
state
contain
varieti
noncleav
dipeptid
isoster
core
scaffold
mimic
transit
state
substrat
cleavag
thu
although
chemic
differ
mani
pi
close
overlap
structur
interact
introduct
pi
begin
highli
activ
antiretrovir
therapi
haart
profound
impact
paradigm
treatment
infect
potenti
chang
often
progress
fatal
infect
chronic
manag
diseas
continu
evolut
pibas
antivir
therapi
due
numer
factor
includ
ongo
need
potent
inhibitor
improv
pharmacokinet
decreas
side
effect
profil
higher
genet
barrier
resist
combat
multidrug
resist
hiv
nine
pi
compound
current
approv
unit
state
food
drug
administr
treatment
infect
fig
follow
saquinavir
sqv
ritonavir
rtv
indinavir
idv
nelfinavir
nfv
lopinavir
lpv
atazanavir
atv
fosamprenavir
fpv
tipranavir
tpv
darunavir
drv
discuss
clinic
use
pi
chronolog
order
fda
approv
saquinavir
sqv
first
shown
vitro
potent
inhibit
acut
infect
cell
ic
subnanomolar
rang
inhibit
viral
matur
chronic
infect
cell
nm
craig
et
al
subsequ
clinic
trial
sqv
monotherapi
infect
men
concentr
mg
three
time
day
week
result
decreas
rna
kitchen
et
al
data
facilit
sqv
becom
first
fdaapprov
pi
decemb
origin
formul
sqv
low
bioavail
due
extens
firstpass
metabol
intestin
liver
cytochrom
character
mutant
decreas
sensit
sqv
reveal
amino
acid
substitut
significantli
increas
ic
concentr
approxim
jacobsen
et
al
turriziani
et
al
thu
need
potent
pi
improv
pharmacokinet
higher
genet
barrier
resist
quickli
becam
appar
ritonavir
rtv
deriv
optim
pharmacokinet
properti
seri
symmetrybas
pi
vitro
studi
demonstr
rtv
potent
antivir
agent
activ
varieti
strain
ic
nm
kempf
et
al
antiretrovir
activ
vivo
demonstr
broad
rang
dose
peak
declin
plasma
viremia
danner
et
al
markowitz
et
al
unfortun
despit
inhibit
rtv
often
result
dosedepend
gi
side
effect
frequent
intoler
side
effect
secondari
mani
uniqu
featur
rtv
high
oral
bioavail
kempf
et
al
potent
inhibit
cytochrom
potent
pi
hoetelman
fortuit
strong
inhibit
metabol
pathway
result
strikingli
long
halflif
rtv
howev
anoth
limit
rtv
monotherapi
low
genet
barrier
resist
mutat
codon
substanti
reduc
viral
suscept
markowitz
et
al
select
proteas
variant
reduc
affin
rtv
consist
hydrophob
interact
rtv
isopropyl
side
chain
val
observ
xray
crystallographi
abil
rtv
inhibit
paradigm
pibas
therapi
chang
use
rtv
singl
pi
boost
pi
rtv
increas
halfliv
kempf
et
al
becom
standard
maintain
prolong
blood
level
boost
pi
increas
potenc
decreas
requir
dosag
minim
pi
side
effect
similar
fashion
rtv
boost
impact
dose
requir
class
antivir
agent
includ
coreceptor
antagonist
maraviroc
indinavir
final
design
idv
includ
element
improv
absorpt
bioavail
addit
basic
amin
backbon
hydroxyethylen
transitionst
mimic
compound
idv
demonstr
vitro
inhibit
varieti
isol
ic
nm
rang
vacca
et
al
monotherapi
trial
demonstr
declin
rna
level
stein
et
al
genet
correl
vivo
resist
reveal
variabl
pattern
multipl
substitut
indic
resist
evolv
multipl
pathway
ongo
replic
howev
resist
isol
typic
substitut
codon
andor
condra
et
al
nelfinavir
use
structurebas
design
conjunct
predict
oral
pharmacokinet
nfv
identifi
found
potent
inhibit
vitro
ic
nm
rang
kaldor
et
al
clinic
trial
nfv
reveal
robust
sustain
reduct
rna
half
subject
attain
persist
log
reduct
month
conjunct
mean
increas
cell
per
mm
markowitz
et
al
subject
viral
rebound
activ
site
mutat
allow
nfv
resist
often
mediat
uniqu
substitut
note
mutat
confer
phenotyp
crossresist
pi
lopinavir
mani
limit
first
gener
pi
modest
oral
bioavail
short
plasma
halflif
high
bind
plasma
protein
strict
dietari
restrict
low
genet
barrier
resist
led
eventu
discoveri
lpv
vitro
studi
lpv
demonstr
inhibit
wild
type
mutant
proteas
ic
subnanomolar
rang
furthermor
lpv
like
pi
exquisit
sensit
pharmacokinet
enhanc
codos
ritonavir
produc
sustain
concentr
plasma
ec
led
coformul
lpvrtv
kaletra
vivo
potent
durabl
viral
suppress
examin
antiretrovir
patient
receiv
lpvrtv
conjunct
two
nucleosid
revers
transcriptas
inhibitor
nrti
patient
viral
load
copiesml
week
murphi
et
al
contrast
first
gener
pi
kaletra
shown
much
higher
genet
barrier
resist
select
highli
resist
viral
variant
due
sequenti
appear
multipl
mutat
carrillo
et
al
moreov
mutat
amino
acid
posit
proteas
associ
reduc
suscept
must
appear
combin
median
ic
lpv
isol
mutat
higher
respect
ic
wildtyp
kempf
et
al
genotyp
inhibitori
quotient
relationship
lpv
trough
level
number
pro
mutat
main
independ
predictor
respons
lpvrtv
gonzalez
de
requena
et
al
reinforc
potenc
high
resist
barrier
smallscal
clinic
trial
shown
twothird
patient
kaletra
alon
capabl
maintain
suppress
limit
detect
rna
copiesml
year
followup
pulido
et
al
atazanavir
design
simplifi
drug
dose
regimen
atv
approv
becam
first
daili
pi
vitro
atv
robust
antihiv
activ
ic
less
nm
ic
nm
cell
cultur
robinson
et
al
phase
clinic
trial
show
efficaci
atv
combin
didanosin
stavudin
patient
week
mean
reduct
baselin
rna
log
half
patient
viral
load
copiesml
sann
et
al
contrast
pi
especi
boost
rtv
atv
associ
clinic
relev
dyslipidemia
insulin
resist
larg
scale
phase
trial
confirm
find
reveal
noninferior
atv
vs
nonnucleosid
revers
transcriptas
inhibitor
nnrti
efavirenz
conjunct
two
nrti
combivir
squir
et
al
atvrtv
vs
lpvrtv
johnson
atv
distinct
resist
profil
rel
pi
suscept
maintain
isol
resist
pi
colonno
et
al
howev
uniqu
substitut
shown
signatur
mutat
resist
atv
fosamprenavir
fpv
inact
highli
water
solubl
phosphat
ester
prodrug
amprenavir
apv
pi
includ
sulfonamid
moieti
fpv
synthes
allow
decreas
pill
burden
improv
patient
complianc
complet
hydrolyz
apv
gut
endothelium
although
apv
fdaapprov
april
product
discontinu
fpv
becam
avail
octob
initi
vitro
studi
apv
demonstr
potent
inhibit
mean
ic
nm
six
hiv
clinic
isol
st
clair
et
al
two
pivot
larg
scale
clinic
trial
demonstr
superior
fpv
vs
nfv
contribut
suppress
viral
rna
load
neat
rodriguezfrench
et
al
solo
trial
macmanu
et
al
like
second
gener
pi
fpv
select
unusu
vitro
resist
profil
multipl
substitut
codon
need
confer
highlevel
resist
partaledi
et
al
tipranavir
contrast
previous
approv
pi
classifi
peptidomimet
transit
state
analog
structur
similar
tetrahedr
intermedi
form
hydrolyt
cleavag
peptid
bond
natur
substrat
randolph
degoey
tpv
first
nonpeptid
pi
dihydropyron
sulfonafamid
class
structur
similar
coumadin
initi
vitro
data
demonstr
tpv
promis
candid
develop
popp
et
al
vitro
studi
demonstr
potent
inhibit
tpv
clinic
isol
resist
multipl
pi
due
molecular
flexibl
allow
tpv
fit
activ
site
pr
becom
resist
pi
plosker
figgitt
rusconi
et
al
phase
ii
clinic
trial
shown
mani
pro
mutat
includ
least
three
pi
resistanceassoci
mutat
need
confer
decreas
suscept
plosker
figgitt
random
evalu
strateg
intervent
multidrug
resist
patient
resist
resist
trial
cahn
et
al
gath
et
al
assess
safeti
efficaci
boost
tpv
vs
boost
pi
lpv
sqv
apv
idv
set
optim
background
regimen
week
half
patient
fewer
pi
mutat
vs
compar
picontain
arm
respond
therapi
log
declin
baselin
viral
rna
p
week
proport
patient
undetect
viral
load
copiesml
significantli
greater
tpv
arm
vs
compar
arm
vs
respect
p
darunavir
drv
second
nonpeptid
pi
synthes
replac
tetrahydrofuranyl
thf
urethan
moieti
amprenavir
bisthf
compon
koh
et
al
addit
hydrogen
bond
bisthf
ring
pi
backbon
result
activ
broad
rang
clinic
isol
ic
nanomolar
rang
includ
multidrugresist
phase
iib
clinic
trial
perform
evalu
treatment
experienc
patient
pi
resist
examin
highli
treatmentexperienc
patient
randomli
assign
either
drvrtv
compar
boost
pi
sqv
apv
sqv
atv
proport
patient
achiev
viral
suppress
rna
copiesml
vs
drv
vs
compar
arm
respect
subset
analys
reveal
significantli
greater
proport
patient
receiv
drv
eight
pi
resist
mutat
achiev
viral
load
copiesml
week
vs
patient
receiv
compar
pi
vs
respect
viral
load
suppress
sustain
least
week
drvrtv
patient
vs
compar
patient
viral
load
reduct
log
copiesml
clotet
et
al
surfac
plasmon
reson
technolog
use
analyz
uniqu
bind
kinet
drv
substrat
explain
potent
antivir
activ
dissoci
halflif
drv
found
significantli
greater
analyz
pi
fpv
atv
lpv
tpv
bind
affin
drv
order
magnitud
higher
vs
pi
dierynck
et
al
nearli
residu
proteas
known
mutat
hoffman
et
al
johnston
et
al
rhee
et
al
wu
et
al
mani
mutat
higher
frequenc
patient
undergo
antiretrovir
therapi
although
site
consid
primari
drugresist
mutat
occur
complex
interdepend
combin
mani
site
throughout
enzym
site
mutat
within
outsid
activ
site
addit
specif
coevolut
sequenc
particular
cleavag
site
becom
evid
residu
conserv
appear
primarili
enzymat
activ
structur
reason
dimer
interfac
flexibl
key
glycin
residu
extens
mutat
pattern
enzym
substrat
indic
plastic
adapt
target
chapter
provid
detail
inform
resist
develop
antivir
therapi
fundament
level
mutat
confer
drug
resist
maintain
function
proteas
impli
enzym
continu
recogn
cleav
divers
set
substrat
sequenc
permit
viral
matur
sinc
proteas
inhibitor
competit
activ
site
inhibitor
substrat
resist
occur
without
impact
substrat
recognit
somewhat
dilemma
compar
crystal
structur
substrat
complex
crystal
structur
inhibitor
complex
found
king
et
al
inhibitor
protrud
substrat
envelop
specif
locat
posit
inhibitor
protrud
away
substrat
contact
proteas
correspond
close
site
drug
resist
mutat
king
et
al
prabujeyabalan
et
al
fact
inhibitor
fit
tightli
within
substrat
envelop
higher
threshold
drug
resist
apv
drv
king
et
al
thu
drug
resist
potenti
greatli
limit
restrict
inhibitor
fit
within
substrat
envelop
region
test
inhibitor
design
strategi
recent
util
result
number
high
affin
novel
proteas
inhibitor
retain
flat
bind
profil
drugresist
proteas
variant
altman
et
al
chellappan
et
al
howev
resistanceassoci
mutat
exist
throughout
enzym
like
role
maintain
activ
fit
enzym
sever
virus
flavivirida
famili
target
antivir
develop
hepat
c
viru
hcv
hepaciviru
genu
greatest
impact
human
popul
dengu
viru
flaviviru
genu
also
repres
import
human
pathogen
vaccin
avail
envelop
virus
plusstrand
rna
genom
approxim
kb
genom
encod
singl
larg
precursor
protein
approxim
amino
acid
includ
structur
nonstructur
viral
protein
viral
replic
take
place
cytoplasm
infect
cell
earli
character
hcv
polyprotein
process
enzym
involv
review
bartenschlag
presenc
chymotrypsinlik
serin
proteas
first
infer
base
sequenc
comparison
presenc
place
within
aminotermin
third
protein
ctermin
twothird
encod
helicas
activ
proteas
activ
respons
four
ten
cleavag
occur
larg
precursor
protein
immedi
downstream
product
subunit
proteas
greatli
increas
level
catalyt
activ
give
rise
name
extens
work
understand
natur
proteas
culmin
determin
structur
atom
resolut
kim
et
al
love
et
al
structur
confirm
relationship
member
chymotrypsin
famili
overal
structur
doubl
one
structur
kim
et
al
includ
peptid
repres
cofactor
peptid
form
one
eight
make
ntermin
proteas
whose
presenc
help
form
expect
catalyt
triad
juxtapos
structur
form
activ
site
structur
also
reveal
rel
shallow
substrat
bind
cleft
fig
comparison
proteas
cleavag
site
show
three
posit
conserv
edxxxxctsa
bartenschlag
avail
robust
recombin
enzym
assay
reveal
enzym
recogn
ten
amino
acid
stretch
substrat
steinkuhl
et
al
zhang
et
al
cy
major
determin
cleavag
site
recognit
bartenschlag
structur
confirm
earlier
model
studi
place
phe
residu
bottom
subsit
posit
allow
van
der
yao
et
al
serin
proteas
domain
shown
cyan
catalyt
triad
highlight
yellow
helicas
domain
magenta
waal
interact
cy
also
locat
basic
arg
ly
residu
posit
interact
acid
residu
detail
bind
ntermin
ie
p
residu
part
substrat
subsequ
infer
nmr
studi
show
interact
ntermin
segment
substrat
enzym
larg
confin
within
ctermin
cicero
et
al
character
peptid
substrat
led
observ
ntermin
peptid
product
abl
inhibit
enzym
llinasbrunet
et
al
steinkuhl
et
al
prove
use
start
point
inhibitor
design
first
optim
sequenc
peptid
inhibitor
ingallinella
et
al
subsequ
use
nonpeptid
substitu
detail
review
hcv
proteas
inhibitor
develop
found
lin
carfi
major
limit
develop
antihcv
compound
lack
viru
replic
system
final
overcom
develop
novel
replicon
system
direct
persist
replic
cell
cultur
format
lohmann
et
al
use
system
possibl
demonstr
antivir
activ
inhibitor
cell
cultur
assay
demonstr
potenc
par
treatment
paus
et
al
first
inhibitor
develop
point
test
human
biln
celuprevir
inhibitor
tripeptid
mimet
substrat
residu
includ
rigidifi
structur
link
equival
side
chain
macrocycl
structur
competit
inhibitor
ki
rang
nm
ec
cell
cultur
tenfold
higher
shortterm
clinic
trial
log
decreas
viral
rna
load
observ
two
day
drug
administr
follow
viru
rebound
cessat
result
confirm
larger
group
subject
infect
hcv
hinrichsen
et
al
howev
decreas
variabl
subject
infect
genotyp
reiser
et
al
unfortun
develop
compound
suspend
due
toxic
second
proteas
inhibitor
develop
point
clinic
trial
mimet
peptid
repres
cleavag
site
novel
featur
design
inclus
group
c
terminu
posit
keto
carbonyl
abl
form
revers
coval
bond
nucleophil
activ
site
perni
et
al
inhibitor
ki
nm
ec
higher
cell
cultur
replicon
assay
initi
phase
dose
studi
administr
week
period
log
drop
viral
rna
load
blood
subject
reesink
et
al
although
maximum
drop
seen
day
follow
rebound
viru
blood
coadministr
telaprevir
block
rebound
within
week
period
third
inhibitor
develop
sch
boceprevir
inhibitor
also
use
ketoamid
strategi
form
coval
bond
case
repres
mimet
although
cap
group
occupi
venkatraman
et
al
initi
phase
dose
studi
show
potenc
human
enhanc
coadministr
sarrazin
et
al
inhibitor
earlier
stage
develop
macrocycl
inhibitor
shown
good
potenc
vitro
high
bioavail
simmen
et
al
anoth
macrocycl
inhibitor
enter
earli
clinic
trial
appear
twostep
bind
mechan
result
noncoval
bind
slow
dissoci
rajagopalan
et
al
treatment
hcv
strong
parallel
treatment
specif
need
suppress
viral
replic
major
advantag
hcv
treatment
compar
treatment
sustain
suppress
hcv
lead
complet
clearanc
viru
cure
treatment
use
sever
agent
togeth
give
better
sustain
viral
respons
compar
use
singl
agent
current
therapi
ribavirin
success
rate
week
treatment
peopl
genotyp
treatment
success
subject
genotyp
week
treatment
http
digestiveniddknihgovddiseasespubschronichepc
futur
studi
initi
combin
new
agent
approv
therapi
ribavirin
howev
use
combin
new
agent
known
virusspecif
target
major
goal
experiment
evid
gener
use
inhibit
replicon
cell
culturebas
assay
support
use
agent
differ
viral
target
wyle
et
al
import
mileston
avoid
use
reduc
time
therapi
reach
sustain
viral
respons
interim
result
phase
trial
report
subject
infect
genotyp
hcv
design
dose
telaprevir
ribavirin
week
variabl
therapi
tail
ribavirin
initi
week
time
point
viral
rna
suppress
subject
compar
receiv
ribavirin
jacobson
et
al
addit
six
nine
subject
receiv
three
drug
week
without
tail
therapi
achiev
sustain
viral
respons
three
show
evid
select
telaprevir
resist
week
respons
viral
rna
suppress
treatment
telaprevir
plu
ribavirin
dual
therapi
telaprevir
compar
ribavirin
result
consist
idea
ad
combin
agent
result
improv
respons
although
effect
sustain
viral
respons
rate
yet
determin
interim
result
phase
trial
boceprevir
sch
releas
subject
receiv
boceprevir
plu
ribavirin
viral
rna
load
suppress
week
subject
infect
genotyp
hcv
compar
ribavirin
standard
care
arm
wwwschploughcomsch
ploughnewsreleas
jsp
releaseid
howev
yet
known
enhanc
earli
respons
translat
sustain
respons
resist
inhibitor
primarili
test
use
replicon
system
tissu
cultur
close
parallel
seen
resist
pi
specif
incomplet
suppress
viral
replic
allow
select
variant
mutat
reduc
sensit
inhibitor
also
hold
true
clinic
test
unresolv
question
extent
differ
proteas
inhibitor
select
differ
resist
mutat
question
complic
fact
differ
level
drug
select
differ
mutat
resist
go
differ
pathway
give
stochast
featur
appear
resist
cell
cultur
select
scheme
gener
involv
rel
small
sampl
size
ad
stochast
natur
result
resist
evolv
vivo
may
includ
lowlevel
variant
detect
potenti
avail
seed
rapid
outgrowth
resist
variant
therapi
switch
lesson
date
proteas
inhibitor
improv
drug
potenc
much
effect
strategi
deal
resist
within
proteas
inhibitor
drug
class
attempt
design
drug
elicit
nonoverlap
resist
pattern
chapter
provid
detail
inform
resist
develop
hcv
antivir
therapi
dengu
viru
member
flaviviru
genu
flavivirida
famili
number
peopl
risk
dengu
viru
infect
billion
attend
risk
progress
dengu
hemorrhag
fever
lack
avail
vaccin
develop
antivir
dengu
viru
proteas
import
goal
unlik
hcv
activ
subunit
dengu
viru
proteas
come
proteolyt
fragment
upstream
protein
fragment
aria
et
al
chamber
et
al
recent
crystal
structur
dengu
viru
proteas
clarifi
number
issu
especi
compar
structur
west
nile
viru
proteas
bound
inhibitor
erbel
et
al
proteas
similar
doubl
structur
fragment
contribut
part
sheet
inhibitorbound
state
fragment
extens
contact
around
proteas
domain
also
contribut
substrat
bind
site
intim
interact
help
explain
profound
requir
fragment
signific
activ
yusof
et
al
distinct
featur
proteas
target
cleavag
site
presenc
arg
residu
review
melino
paci
howev
subsit
strong
stack
interact
side
chain
interact
base
electrostat
interact
erbel
et
al
given
known
substrat
catalyt
mechan
drug
discoveri
effort
undertaken
although
none
progress
clinic
trial
melino
paci
sinc
mani
differ
virus
encod
essenti
proteas
possibl
envis
develop
potent
proteas
inhibitor
virus
given
knowledg
process
site
sequenc
catalyt
mechan
time
interest
develop
inhibitor
limit
set
virus
caus
chronic
diseas
virus
potenti
caus
larg
scale
epidem
virus
suffici
ubiquit
treat
acut
infect
would
benefici
even
infect
ultim
selflimit
later
review
one
exampl
case
human
cytomegaloviru
hcmv
human
herpesviru
herpesvirida
famili
betaherpesvirina
subfamili
cytomegaloviru
genu
larg
envelop
doublestrand
dna
viru
infect
rate
gener
popul
asymptomat
infect
healthi
individu
howev
becom
immunocompromis
immunosuppress
result
enhanc
replic
lead
pneumonia
retin
addit
congenit
infect
newborn
lead
neurolog
abnorm
avail
therapi
base
nucleosid
analog
signific
toxic
herpesviru
proteas
first
describ
hcmv
liu
roizman
welch
et
al
proteas
call
assemblin
encod
hcmv
gene
aminotermin
part
precursor
protein
ctermin
domain
precursor
viral
assembl
protein
cleavag
event
within
precursor
requir
packag
viral
dna
review
brignol
gibson
crystal
structur
hcmv
proteas
chen
et
al
qiu
et
al
shieh
et
al
tong
et
al
bound
inhibitor
khayat
et
al
tong
et
al
reveal
number
featur
target
review
tong
core
enzym
seven
strand
structur
repres
novel
fold
serin
proteas
addit
catalyt
triad
serhishi
rather
familiar
serhisasp
combin
novel
fold
repres
third
independ
evolut
serin
proteas
addit
trypsin
subtilisin
famili
proteas
crystal
dimer
activ
form
enzym
dark
et
al
margosiak
et
al
howev
two
activ
site
dimer
displac
dimer
appear
stabil
structur
activ
site
distanc
structur
chang
bind
substrat
induc
fit
substrateinhibitor
bind
extend
conform
form
antiparallel
align
scissil
bond
activ
site
solvent
expos
remain
side
chain
interact
proteas
given
known
mechan
catalysi
serin
nucleophil
consensu
substrat
sequenc
v
l
xa
possibl
carri
drug
discoveri
effort
seri
inhibitor
base
differ
chemic
backbon
describ
share
activ
carbonyl
react
chemic
nucleophil
review
tong
howev
date
none
compound
made
clinic
develop
given
outcom
altern
screen
develop
allow
high
throughput
screen
cellbas
assay
altern
screen
base
inhibit
enzymat
activ
exampl
cottier
et
al
final
potenti
similar
drug
develop
effort
exist
herpesvirus
kshv
although
littl
work
done
date
altern
approach
develop
inhibitor
explor
kshv
proteas
target
dimer
interfac
block
essenti
step
dimer
shimba
et
al
rhinovirus
caus
signific
fraction
common
cold
suffer
human
popul
howev
member
rhinoviru
genu
picornavirida
famili
includ
differ
serotyp
infect
human
make
vaccin
strategi
impract
thu
altern
strategi
need
interven
nonlifethreaten
inconveni
infect
rhinoviru
like
polioviru
synthes
larg
precursor
protein
matur
viral
protein
gener
two
viral
proteas
involv
cleavag
proteas
cleav
polyprotein
precursor
n
terminu
proteas
respons
addit
cleavag
event
gener
matur
viral
protein
proteas
releas
polyprotein
precursor
cleavag
occur
glngli
flank
sequenc
affect
effici
review
racaniello
structur
analysi
rhinoviru
hepat
viru
proteas
allair
et
al
matthew
et
al
confirm
earlier
predict
picornaviru
proteas
similar
chymotrypsinlik
serin
proteas
fold
import
differ
serin
nucleophil
serin
proteas
replac
cystein
howev
proteas
structur
distinct
eukaryot
cystein
proteas
class
enzym
varieti
design
explor
develop
inhibitor
rhinoviru
proteas
review
tong
inhibitor
design
aid
structur
studi
bound
inhibitor
matthew
et
al
one
success
design
inhibitor
includ
unsatur
ethyl
ester
allow
format
coval
bond
proteas
activ
site
cy
known
michael
acceptor
use
strategi
irrevers
inhibitor
one
compound
rupintrivir
develop
show
efficaci
set
experiment
induc
human
rhinoviru
infect
hayden
et
al
abil
select
resist
rupintrivir
valid
proteas
drug
target
mutat
posit
subsit
common
binford
et
al
howev
rupintrivir
fail
show
efficaci
set
natur
infect
patick
et
al
relat
compound
compound
identifi
signific
bioavail
taken
oral
compound
taken
efficaci
trial
review
patick
limit
rapid
identif
infect
agent
make
develop
agentspecif
therapeut
challeng
given
number
virus
give
coldlik
symptom
like
amelior
earli
intervent
new
coronaviru
quickli
identifi
outbreak
atyp
pneumonia
southern
china
earli
new
viru
eventu
caus
infect
approxim
death
countri
condit
name
sever
acut
respiratori
syndrom
sar
caus
coronaviru
name
sarscov
zoonot
natur
infect
came
identif
similar
viru
bat
poon
et
al
although
possibl
bat
viru
pass
anim
host
recombin
sarslik
coronavirus
prior
infect
human
hon
et
al
sarscov
current
circul
human
popul
howev
mysteri
appear
rapid
spread
viru
emphas
vulner
human
popul
respiratori
infect
spur
interest
develop
antivir
could
use
either
treatment
prophylaxi
complement
public
health
measur
curb
futur
outbreak
sarscov
classifi
nidoviral
order
coronavirida
famili
coronaviru
genu
wwwvirustaxonomyonlinecom
genom
approxim
kb
gene
express
accomplish
gener
cotermin
subgenom
messag
replicas
gene
encod
two
larg
overlap
read
frame
term
encod
polyprotein
undergo
extens
proteolyt
process
two
viral
proteas
major
cleavag
event
mediat
viral
also
call
main
proteas
review
liang
cleavag
site
conserv
posit
gln
ser
ala
gli
posit
leu
met
phe
posit
ala
val
pro
thr
posit
suggest
similar
coronaviru
picornaviru
proteas
confirm
extend
structur
proteas
determin
sever
coronavirus
includ
sar
anand
et
al
lee
et
al
xue
et
al
yang
et
al
proteas
contain
three
domain
two
ntermin
domain
compris
two
chymotrypsin
fold
similar
trypsinchymotrypsin
picornaviru
proteas
ctermin
domain
iii
globular
compos
seri
unknown
function
crystal
structur
also
confirm
earlier
biochem
work
enzym
dimer
unusu
arrang
subunit
perpendicular
like
picornaviru
proteas
proteas
replac
chymotrypsin
activ
site
serin
cystein
sar
proteas
along
make
catalyt
dyad
rather
prototyp
catalyt
triad
subsit
accommod
gln
specif
interact
histidin
place
bottom
subsit
hydrophob
side
chain
accommod
larg
hydrophob
subsit
side
chain
keep
poor
conserv
orient
toward
solvent
side
chain
must
small
amino
acid
fit
shallow
subsit
initi
search
inhibitor
sar
proteas
focus
preexist
drug
compound
test
empir
other
select
base
model
pi
nelfinavir
lopinavirritonavir
consid
latter
actual
use
clinic
sar
covinfect
subject
rhinoviru
inhibitor
ruprintrivir
relat
compound
also
test
review
fear
et
al
howev
absenc
element
specif
preexist
compound
would
expect
low
potenc
focus
effort
drug
develop
use
either
lead
compound
identifi
initi
screen
start
substrat
mimet
mani
approach
use
inhibitor
bind
irrevers
activ
site
cy
occupi
enzym
subsit
complet
studi
analyz
enzym
inhibit
inhibit
viral
replic
structur
studi
inhibitor
bound
enzym
studi
includ
substratebas
inhibitor
chloromethyl
keton
group
yang
et
al
substratebas
inhibitor
michael
acceptor
xue
et
al
yang
et
al
peptidomimet
aldehyd
acceptor
peptidomimet
inhibitor
reactiv
phthalhydrazid
group
yin
et
al
substratebas
inhibitor
epoxyketon
reactiv
group
goetz
et
al
talli
repres
sampl
drug
discoveri
effort
direct
sar
cov
proteas
appear
sar
cov
reveal
new
threat
human
health
clear
similar
virus
recombin
virus
could
emerg
wide
rang
anim
analog
recur
introduct
influenza
viru
migratori
bird
popul
thu
may
advantag
design
less
potent
inhibitor
broad
spectrum
coronavirus
sinc
drug
develop
slow
process
compar
spread
epidem
respiratori
viru
like
abl
blunt
initi
acut
viremia
may
suffici
provid
clinic
benefit
toxic
potenc
may
less
critic
short
cours
therapi
compar
treat
chronic
infect
like
hcv
tool
appear
place
develop
proteas
inhibitor
allow
target
clinic
intervent
futur
outbreak
howev
challeng
experi
demonstr
efficaci
possibl
potenc
model
system
dose
studi
healthi
volunt
like
replac
lengthi
clinic
efficaci
trial
requir
typic
drug
scenario
sar
cov
inhibitor
would
made
avail
next
epidem
compassion
use
basi
